Merck KGaA Hopes UK Cancer Charity R&D Pact Will Yield New Assets

The multi-project collaboration and licensing deal between charities Cancer Research UK and Germany's Merck aims to discover and commercialize novel cancer treatment assets.

R&D
Merck has Global Rights to molecules discovered by Its New UK R&D Pact • Source: Shutterstock

Merck of Germany is building on its drug discovery collaboration with charity Cancer Research UK and The Institute of Cancer Research, London, with a multi-project deal which, if successful, would give Merck KGAA worldwide rights to take molecules discovered into clinical development.

This three-project alliance follows previous single project drug discovery collaborations and a more recent target validation collaboration between Merck and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.